SERDA therapeutics submits IND for its lead product, an innovative wound debridement agent.

AMSTERDAM, THE NETHERLANDS, 23 February 2023. SERDA therapeutics, a biopharmaceutical company, announces that it has submitted an Investigational New Drug Application (IND) to the US FDA on the 17th February, 2023 for its lead product SN514 hydrogel, an innovative enzymatic wound debriding agent. Clinical studies are expected to start in Q2 2023. SN514 hydrogel is […]